Evaluation of Safety and Tolerability of Long-term TEV-50717 for Treatment of Tourette Syndrome
- Study Title
- Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents
- Teva Identifier
- TV50717-CNS-30047 | 2016-000630-22
- ClinicalTrials.gov Identifier
- NCT03567291
- Study Status
- Terminated
- Trial Condition(s)
- Tourette Syndrome
- Interventions
- Drug: TEV-50717 | Drug: Placebo
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Child
- Age Range
- 6 Years to 17 Years
- Trial Duration
- May 25, 2018 - May 15, 2020
- Phase
- Phase 3
